» Articles » PMID: 18772890

Comprehensive Genomic Characterization Defines Human Glioblastoma Genes and Core Pathways

Overview
Journal Nature
Specialty Science
Date 2008 Sep 6
PMID 18772890
Citations 4228
Affiliations
Soon will be listed here.
Abstract

Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide substitutions and epigenetic modifications that drive malignant transformation. The Cancer Genome Atlas (TCGA) pilot project aims to assess the value of large-scale multi-dimensional analysis of these molecular characteristics in human cancer and to provide the data rapidly to the research community. Here we report the interim integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in 206 glioblastomas--the most common type of adult brain cancer--and nucleotide sequence aberrations in 91 of the 206 glioblastomas. This analysis provides new insights into the roles of ERBB2, NF1 and TP53, uncovers frequent mutations of the phosphatidylinositol-3-OH kinase regulatory subunit gene PIK3R1, and provides a network view of the pathways altered in the development of glioblastoma. Furthermore, integration of mutation, DNA methylation and clinical treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated glioblastomas, an observation with potential clinical implications. Together, these findings establish the feasibility and power of TCGA, demonstrating that it can rapidly expand knowledge of the molecular basis of cancer.

Citing Articles

Optimizing sample size for supervised machine learning with bulk transcriptomic sequencing: a learning curve approach.

Qi Y, Wang X, Qin L Brief Bioinform. 2025; 26(2).

PMID: 40072846 PMC: 11899567. DOI: 10.1093/bib/bbaf097.


Long-Chain Cyclic Arylguanidines as Multifunctional Serotonin Receptor Ligands with Antiproliferative Activity.

Zareba P, Drabczyk A, Wnorowski A, Maj M, Rurka P, Malarz K ACS Omega. 2025; 10(7):6446-6469.

PMID: 40028084 PMC: 11866022. DOI: 10.1021/acsomega.4c06456.


The radiogenomic and spatiogenomic landscapes of glioblastoma and their relationship to oncogenic drivers.

Kazerooni A, Akbari H, Hu X, Bommineni V, Grigoriadis D, Toorens E Commun Med (Lond). 2025; 5(1):55.

PMID: 40025245 PMC: 11873127. DOI: 10.1038/s43856-025-00767-0.


Transitioning from molecular methods to therapeutic methods: An in‑depth analysis of glioblastoma (Review).

Han H, Du A, Li J, Han H, Feng P, Zhu Y Oncol Rep. 2025; 53(4).

PMID: 40017136 PMC: 11894601. DOI: 10.3892/or.2025.8881.


Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.

PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.


References
1.
Yang J, Qu X, Yu Y, Kohn E, Friedlander M . Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency. Int J Cancer. 2008; 123(2):258-263. DOI: 10.1002/ijc.23535. View

2.
Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau L . Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004; 64(18):6503-10. DOI: 10.1158/0008-5472.CAN-04-0452. View

3.
Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M . Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med. 1997; 336(24):1713-20. DOI: 10.1056/NEJM199706123362404. View

4.
Taylor B, Barretina J, Socci N, Decarolis P, Ladanyi M, Meyerson M . Functional copy-number alterations in cancer. PLoS One. 2008; 3(9):e3179. PMC: 2527508. DOI: 10.1371/journal.pone.0003179. View

5.
Bader A, Kang S, Zhao L, Vogt P . Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005; 5(12):921-9. DOI: 10.1038/nrc1753. View